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Enschede, The NetherlandsA B S T R A C THealth care decisions are complex and involve confronting trade-offs
between multiple, often conﬂicting, objectives. Using structured,
explicit approaches to decisions involving multiple criteria can
improve the quality of decision making and a set of techniques,
known under the collective heading multiple criteria decision analysis
(MCDA), are useful for this purpose. MCDA methods are widely used
in other sectors, and recently there has been an increase in health
care applications. In 2014, ISPOR established an MCDA Emerging Good
Practices Task Force. It was charged with establishing a common
deﬁnition for MCDA in health care decision making and developing
good practice guidelines for conducting MCDA to aid health care
decision making. This initial ISPOR MCDA task force report provides
an introduction to MCDA - it deﬁnes MCDA; provides examples of itsee front matter & 2016 Published by Elsevier Inc.
(ISPOR).
.1016/j.jval.2015.12.003
@shefﬁeld.ac.uk.
ndence to: Praveen Thokala, the University of Sheuse in different kinds of decision making in health care (including
beneﬁt risk analysis, health technology assessment, resource alloca-
tion, portfolio decision analysis, shared patient clinician decision
making and prioritizing patients’ access to services); provides an
overview of the principal methods of MCDA; and describes the key
steps involved. Upon reviewing this report, readers should have a
solid overview of MCDA methods and their potential for supporting
health care decision making.
Keywords: decision making, health care, MCDA, multiple criteria
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& 2016 Published by Elsevier Inc. on behalf of International Society for
Pharmacoeconomics and Outcomes Research (ISPOR).Introduction
Health care decisions are rarely simple with easy answers. Complex-
ity in these decisions is inevitable, whether a high-level decision,
such as that made by a budget holder, allocating limited resources
across treatments, or at the micro level, such as a patient’s decision
on the best treatment alternative. Multiple factors impact these
decisions, a number of alternatives exist, and the information
available about each alternative is often imperfect. The cognitive
burden involved can lead to the use of heuristics—in effect, mental
shortcuts, such as adopting a “rule of thumb”—and systematicmistakes [1]. It can be a Herculean effort to assess the alternatives
and the relevant evidence to make a good, informed decision.
Decision makers, whether they are individuals or committees,
have difﬁculty processing and systematically evaluating relevant
information. This assessment process involves confronting trade-
offs between the alternatives under consideration. Each decision
maker will need to prioritize what matters most. If more than one
individual is involved, the priorities of involved decision makers can,
and frequently do, conﬂict, increasing the difﬁculty and complexity
of the decision-making process. Despite this complexity, decisions
are made: even sticking with status quo is itself a decision. Relyingon behalf of International Society for Pharmacoeconomics and
fﬁeld, HEDS, ScHARR, Regent Court, 30 Regent Street, Shefﬁeld S1
Background to the Task Force
In May 2014, the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) Health Science Policy Council recom-
mended to the ISPOR Board of Directors that an ISPOR Emerging
Good Practices Task Force on multiple criteria decision analysis
(MCDA) and its use in health care decision making be established.
MCDA comprises a broad set of methodological approaches from
operations research now being used increasingly in the health care
sector. The task force goal was to provide a foundational report on
the topic, an MCDA primer, and then focus on initial recommenda-
tions on how best to use MCDA methods to support health care
decision making.
The task force leadership group comprises experts in health
technology assessment, health care research, modeling, pricing,
formulary development, epidemiology, and economics. Task force
members were selected to represent a diverse range of perspec-
tives. They work in hospital health systems, health technology
assessment agencies, research organizations, academia, and the
insurance and pharmaceutical industries. The task force had
international representation with members from the United King-
dom, Belgium, Canada, the Netherlands, Sweden, Hungary, and the
United States, in addition to reviewers from around the world.
The task force met approximately every four weeks by
teleconference to develop detailed outlines and discuss issues
and revisions. In addition, task force members met in person at
ISPOR International Meetings and European Congresses. The
four co-chairs taught an MCDA course at two of these ISPOR
meetings and presented their preliminary findings at workshop
and forum presentations multiple times. The final reports were
presented at the Third Plenary of the ISPOR 18th European
Congress in Milan.
Many comments were received during these presentations.
Equally, if not more importantly, both reports were submitted for
review twice. Nearly 50 ISPOR members knowledgeable on the
topic submitted substantive written comments during these
review rounds. All comments were considered. These were
discussed by the task force on a series of teleconferences and
during a 1.5-day task force face-to-face consensus meeting.
Comments were addressed as appropriate in subsequent ver-
sions of the report. We gratefully acknowledge our reviewers for
their contribution to the task force consensus development
process and to the quality of these ISPOR MCDA task force
reports.
All written comments are published at the ISPOR Web site
on the task force’s Web page: http://www.ispor.org/Multi-
Criteria-Decision-Analysis-guideline.asp. The task force re-
port and Web page may also be accessed from the ISPOR
homepage (www.ispor.org) via the purple Research Tools
menu, ISPOR Good Practices for Outcomes Research, heading:
Use of Outcomes Research in Health Care Decisions.
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decisions.
Without a formal process to evaluate alternatives and prior-
ities, there may be inconsistency, variability, or a lack of predict-
ability on a particular factor’s or criterion’s importance in the
decision. The decision makers’ credibility and potentially legiti-
macy may come into question, and this is especially true for
accountability on a decision made by a public body if there is a
lack of transparency about how a decision was made. For
example, it is argued that health technology assessment (HTA)
agencies should aim to be transparent about the decision-making
process to ensure fair resource allocation [2].
The decision-making process can be improved by working
with decision makers and stakeholders providing support and
structure to the process. Using structured, explicit approaches to
decisions involving multiple criteria can improve the quality of
decision making and a set of techniques, known under the
collective heading multiple criteria decision analysis (MCDA),
are useful for this purpose. This set of techniques provides clarity
on which criteria are relevant, the importance attached to each,
and how to use this information in a framework for assessing the
available alternatives. By doing so, they can help increase the
consistency, transparency, and legitimacy of decisions.
MCDA comprises a broad set of methodological approaches,
originating from operations research, yet with a rich intellectual
grounding in other disciplines [3]. MCDA methods are widely
used in public-sector and private-sector decisions on transport,
immigration, education, investment, environment, energy,
defense, and so forth [4–6]. The health care sector has been
relatively slow to apply MCDA. But as more researchers and
practitioners have become aware of the techniques, there has
been a sharp increase in its health care application [7].
A challenge for users of MCDA is that there are many MCDA
methods available [8]. These differ not just in how MCDA is put into
practice but also in terms of the fundamental theories and beliefs
underpinning them. The existence of different schools of thought,
representing different positions on how MCDA should be performed,
makes the choice of MCDAmethod to use in any given context quite
complex. This is made still more difﬁcult by the existence of variouscommercial and not-for-proﬁt MCDA “toolkits” promoted by their
developers. The current literature onMCDA in health care offers little
guidance to users on how to choose from the bewildering array of
approaches, on the “best” approach for different types of decisions,
and what the relevant considerations are. In the absence of guidance
on how to implement MCDA techniques in health care, MCDA can be
misused and the decision makers misled [9].
In 2014, ISPOR established an Emerging Good Practices Task
Force, charged with the objectives of establishing a common
deﬁnition for MCDA in health care decision making and devel-
oping good practice guidelines for conducting MCDA to aid health
care decision making. This initial ISPOR MCDA task force report
provides an introduction to MCDA for those unfamiliar with it. It
deﬁnes MCDA, provides examples of its use in different kinds of
decision making in health care, provides an overview of the
principal methods of MCDA, and describes the key steps
involved. The second task force report builds on this by providing
emerging good practice guidelines for selecting the “right”
approach to MCDA in each type of decision and how to imple-
ment these approaches, and also provides a checklist for those
conducting an MCDA. The task force reports do not provide
speciﬁc recommendations for individual applications (e.g., how
MCDA should be used in HTA), and further research is required to
thoroughly address the issues relevant to each decision.A Deﬁnition of MCDA
Keeney and Raiffa’s [10] seminal book on MCDA deﬁnes it as “an
extension of decision theory that covers any decision with multiple
objectives. A methodology for appraising alternatives on individ-
ual, often conﬂicting criteria, and combining them into one overall
appraisal…” An alternative deﬁnition in another inﬂuential text by
Belton and Stewart [11] deﬁnes MCDA as “an umbrella term to
describe a collection of formal approaches, which seek to take
explicit account of multiple criteria in helping individuals or groups
explore decisions that matter.” These deﬁnitions are not mutually
exclusive, and Keeney and Raiffa’s deﬁnition is a subsect of Belton
and Stewart’s deﬁnition. Keeney and Raiffa’s deﬁnition of MCDA
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expression of value, whereas Belton and Stewart’s deﬁnition allows
the possibility of MCDA being used to support deliberation without
the need for aggregation.
The task force adopted a broad approach, including in our
consideration of MCDA methods that help deliberative discus-
sions using explicitly deﬁned criteria, but without quantitative
modeling. For example, evidence on each alternative under
consideration, in terms of its measured performance on each of
the criteria considered to be relevant, can be assembled in a
“performance matrix”—an example is the European Medicine
Agency’s (EMA’s) effects table for beneﬁt-risk analysis (BRA)
[12]. Decision makers can ﬁnd this “partial” form of MCDA a
useful way of summarizing the relevant evidence, to help
structure their deliberations about which alternatives are best.Types of Health Care Decisions Supported by MCDA
Examples of current and potential applications of MCDA in health
care decision making are summarized in Table 1 and detailed in
this section. This is not an exhaustive list, and MCDA can be
useful in many decision contexts. In addition to those mentioned
in Table 1, MCDA has been used to develop disease classiﬁcations
[13,14] and for hospital purchasing [15–17].
These examples in Table 1 demonstrate the diverse range of
decision problems and similarly diverse decision makers/organiza-
tions that MCDA can support. The criteria and stakeholders used in
the MCDA depend on the type of decision problem. The outputs from
the MCDA can be used to support different types of decisions, for
example, to understand the value of the alternatives (e.g., under-
standing the value of treatment for purposes of reimbursement), to
develop a ranking of alternatives (e.g., treatment alternatives for
patients), or to allocate alternatives to a categorical outcome (e.g.,
“approve,” “deny,” or “coverage with evidence development” recom-
mendations for new technologies). Also, the decisions can be one-off
(e.g., patient choosing between treatment alternatives) or repeated (e.
g., reimbursement decisions at HTA agencies).
Although various terms have been used to refer to the value
judgments made during an MCDA—for instance, priorities, pref-
erences, importance, and values—the terminology “preferences”
is adopted in the task force reports. Also, the task force report
refers to decision makers as those who make the choice between
alternatives and stakeholders as the source of preferences. The
task force acknowledges that the term “stakeholders” is used
quite broadly in the health economics literature but within the
MCDA literature, stakeholders are those providing the preferen-
ces and this terminology is used in the task force reports.EMA’s Beneﬁt-Risk Methodology Project
EMA’s Beneﬁt-Risk Methodology Project developed and tested
methods for balancing multiple beneﬁts and risks, which can be
used to inform regulatory decisions about medicinal products.
The project was organized around ﬁve work packages (WPs). WP1
reported on the current practice of beneﬁt-risk assessment in the
European Union regulatory network, and WP2 examined the
applicability of different methods for BRA.
WP3 performed the ﬁeld testing of different methods in ﬁve
European medicine regulatory agencies [19]. The eight-stage
PrOACT-URL framework (Problem formulation, Objectives, Alter-
natives, Consequences, Trade-Offs, Uncertainties, Risk Attitude
and Linked Decisions) was combined with MCDA to perform BRA.
It highlighted the importance of the Effects Table (in essence, a
“performance matrix”) and emphasized the value of the graphical
MCDA displays.WP4 synthesized the results of the earlier WPs to develop
recommendations for undertaking BRA [20]. It suggested that a
full MCDAmodel would be most useful for difﬁcult or contentious
cases, when the beneﬁt-risk balance is marginal and could tip
either way depending on judgements of the clinical relevance of
the effects, favourable or unfavourable, and in the case of many
conﬂicting attributes.
It also suggested that postapproval monitoring of the beneﬁt-
risk balance of a medicinal product in complex or marginal cases
could be supported using quantitative MCDA modeling as the
model can be updated with new information to see whether the
beneﬁt-risk balance has changed.
WP5 involved a 5-month pilot of the use of the “Effects Table”
as a tool to summarize the key beneﬁts and risks and to supple-
ment the beneﬁt-risk section of the Committee for Medicinal
Products for Human Use assessment report [12].
Patient Involvement in HTA: MCDA Pilot by the German
Institute for Quality and Efﬁciency in Health Care
In 2010, the German Institute for Quality and Efﬁciency in Health
Care initiated a study to explore the use of MCDA methods as a
means of incorporating patient involvement into its HTA process.
This was because although patient involvement is widely acknowl-
edged to be important in HTA and health care decision making,
quantitative approaches to ascertain patients’ preferences for treat-
ment end points are not yet established. The project used two
MCDA techniques, the analytic hierarchy process (AHP) and discrete
choice experiments (DCEs), as preference elicitation methods.
The AHP study included two workshops: one with 12 patients,
and one with 7 health care professionals. In the workshops, the
participants rated their preferences with respect to the impor-
tance of different end points of antidepressant treatment by a
pairwise comparison of individual end points. These compari-
sons were then analyzed to generate the relative importance for
each end point [21,38].
In the DCE study, patients and health care professionals were
asked to choose between two (hypothetical) hepatitis C treatment
alternatives that differed in their performance on various treat-
ment characteristics (e.g., outcomes). These choices were ana-
lyzed using logistic regression models to estimate the importance
of the individual treatment characteristics [39].
Both studies concluded that these types of techniques can be
used to support the HTA process, but also highlight some
methodological challenges that need addressing before their
full-scale implementation.
Use of MCDA in HTA Decisions for Universal Coverage in
Thailand
The National Health Security Ofﬁce, the institute that manages
Thailand’s universal coverage scheme, conducted a collaborative
research and development project in the period 2009 to 2010 with
two independent research institutes—the Health Intervention and
Technology Assessment Program and the International Health
Policy Program. The project used MCDA to guide the coverage
decisions on including health interventions in the universal cover-
age scheme health beneﬁt package in Thailand [22].
The process was carried out in four steps—nomination of
interventions for assessment, selection of interventions for
assessment using MCDA, technology assessment of interven-
tions, and appraisal of interventions.
A consultation panel was established which worked with a
large variety of stakeholders to identify potential interventions
and a total of 17 interventions were nominated. The performance
of these 17 interventions was assessed on ﬁve criteria—size of
population affected by disease, effectiveness of health
Table 1 – Examples of health care decisions to which MCDA might be applied.
Type of health
care decision
Examples of who makes
these decisions
Examples of criteria
relevant to the
decision
Examples of
stakeholders
providing
preferences
Examples of
the type of
decisions
Repeated vs “one-off”
decisions
Beneﬁt-risk assessment (BRA) Regulators [18]. See below
for detail of EMA’s
assessment of MCDA as a
method for BRA [12,19,20]
Criteria are the different
aspects of beneﬁts and
risks that are relevant
to each new medicine
under consideration
Regulatory committees
and/or patients
Categorical The relevant risks and
beneﬁts will differ
from case to case. The
criteria and their
importance therefore
differ between
decisions
Health technology assessment
(HTA)
HTA bodies, such as G-BA in
Germany, NICE in
England and Wales, and
PBAC in Australia. See
below for details of
IQWiG’s pilot of MCDA for
HTA [21], Thailand’s use
of MCDA for universal
coverage [22], and the
HTA framework in
Lombardy Region [23]
The criteria used differ
between HTA
systems, but might
include effectiveness,
patient need/burden
of disease/severity.
(Note: the role of cost,
cost- effectiveness,
and budget impact as
criteria in MCDA is
contentious [24,25])
HTA committees or
general public
Categorical, ranking or
understanding “value”
HTA aims to apply an
agreed set of
principles to make
judgments about
reimbursement of
new technologies.
Arguably, the same
principles and criteria
should be used across
repeated decisions, to
ensure consistency
and accountability
Portfolio decision analysis
(PDA)
Decisions made by life
sciences companies,
choosing where best to
direct R&D efforts. See
below for a
pharmaceutical
company’s experience
[26]
The likelihood of success
and projected
proﬁtability (or
consistency with
other company
objectives) of
alternative
investment decisions
Board of directors, or a
committee appointed
by the board
Ranking or understanding
“value”
Can be “one-off” or
“repeated” based on
the decision problem
Commissioning decisions/
priority setting frameworks
(PSFs)
Resource allocation
decisions made by local
budget holders in the
English NHS. Decisions
made by private insurers
about the bundle of
services to reimburse. See
below for details on
English local budget
holders’ experience with
MCDA [27]. Other
examples include the use
of PBMA [28–30], DCE
[31,32], and EVIDEM
[33,34] to set priorities
The criteria used vary
considerably, but
might include
effectiveness, meeting
unmet need/equity
objectives, meeting
government targets,
etc.
Committee in charge of
making the funding
decisions
Ranking These are “repeated”
decisions, inasmuch
as there is a single
ﬁxed budget, and the
criteria used to
prioritize any one
service should also
apply to decisions
about other potential
services, to ensure
consistency and the
achievement of
allocative efﬁciency
continued on next page
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Shared decision making (SDM) Decisions made by patients,
in discussion with their
doctors, about choice of
treatments. See below for
an example of MCDA
being used to assess
cancer screening
alternatives [35]
For example, effect on
life expectancy,
quality of life, side
effects from
treatment, and the
process of care
Patients and clinicians Ranking One-off decisions as the
relevant risks and
beneﬁts will differ
from case to case and
the patients will have
different preferences.
The criteria and their
importance will
therefore differ
between decisions
Prioritizing patients’ access to
health care
Prioritization of patients for
health care services. See
below for the use of
“points systems” to
prioritize patients
awaiting elective surgery
in New Zealand [36].
These can also be used for
transparent, equitable,
and accountable
allocation of scarce
resources, such as solid
organs among patients
waitlisted for
transplantation [37]
Various measures of
patient “need” and
ability to beneﬁt from
treatment
Clinical leaders, patient
groups, and other
health professionals.
Organ procurement
organization at
international,
national, or regional
level
Ranking These often use “points
systems”—algorithmic
approaches that apply
identical criteria and
rules across all cases
to ensure fairness.
These are repeated
decisions coordinated
by a central ofﬁce with
no direct relationship
with patients or their
physicians
DCE, discrete choice experiment; EMA, European Medicines Agency; EVIDEM, Evidence and Value: Impact on Decision Making; G-BA, Der Gemeinsame Bundesausschuss; IQWiG, Institut für
Qualität und Wirtschaftlichkeit im Gesundheitswesen; MCDA, multiattribute decision analysis; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; PBAC,
Pharmaceutical Beneﬁts Advisory Committee; PBMA, Programme Budgeting and Marginal Analysis; R&D, research and development.
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V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 1 – 1 36intervention, variation in practice, economic impact on house-
hold expenditure, and equity and social implications. After
inspection and deliberation, nine interventions were selected
for further quantitative assessment. The nine interventions were
then assessed in terms of their value for money (incremental
cost-effectiveness ratios) and budget impact. Decision makers
qualitatively appraised the information on these nine interven-
tions and deliberated to reach consensus on which interventions
should be adopted in the package.
The study concluded that MCDA has the potential to contrib-
ute to a rational, transparent, and fair priority-setting process.Implementation of European network for Health Technology
Assessment (EUnetHTA) Core Model in Lombardy, Italy
Lombardy Region developed an HTA framework (named Valuta-
zione delle Tecnologie Sanitarie [VTS] [23]) incorporating and
adapting elements from the EUnetHTA Core Model and the
Evidence and Value: Impact on Decision Making (EVIDEM) frame-
work [33]. The VTS framework mapped EUnetHTA domains into
dimensions that Lombardy Region set up to legitimize the
prioritization of technologies and included criteria from the
EVIDEM framework to support the systematic appraisal of the
assessment report into a ﬁnal decision.
The VTS framework is applied in a three-step process com-
prising 1) a prioritization of requests, grounded on a “quick and
dirty” assessment limited to VTS dimensions; 2) a full assess-
ment of the prioritized technologies, provided by answering
EUnetHTA-based issues; and 3) an appraisal of the assessed
technologies, grounded on the analysis of multiple criteria, using
the EVIDEM framework.
The appraisal using the EVIDEM framework is based on 15
explicit quantitative criteria and 6 implicit qualitative criteria.
The appraisal thus results in a quantitative result—that is, the
score for 15 criteria—and 6 qualitative evaluations that are used
to substantiate and legitimize the ﬁnal decision and to commu-
nicate it to the public, the industry, the providers, and other
relevant stakeholders.
The VTS framework has been used in Lombardy Region since
2011 to decide on the introduction and delisting of health
technologies (including diagnostics, devices, interventional pro-
cedures, and drugs). The study concluded that the EUnetHTA
assessment tools can be combined with multiple criteria
appraisal methods to support HTA.Portfolio Decision Analysis in a Pharmaceutical Company
MCDA modeling helped inform ﬁnal portfolio decisions by Aller-
gan by prioritizing the projects on the basis of their value for
money [26].
A 2-day workshop was conducted to elicit stakeholders’
preferences for the different criteria and MCDA modeling was
used to collapse multiple dimensions of beneﬁt into a single risk-
adjusted beneﬁt. The beneﬁt criteria used were net present value
(ﬁnancial value), medical need (extent to which the project will
meet unmet medical need), business impact (protecting the
existing business), future value (contribution to evolution to a
specialty pharmaceutical company), and probability of success
(probability that the beneﬁts will be realized). Risk-adjusted
beneﬁt for each project was estimated by multiplying the beneﬁts
by the probability of realizing them.
The portfolio consisted of 52 projects structured within ﬁve
areas of interest: front and back of eye, skin care, neurological,
and new technologies. Data on the performance of the projects
against the value criteria were estimated, and the projects were
prioritized on the basis of their “risk-adjusted” beneﬁt-to-costratio to maximize the total beneﬁt that can be achieved from a
given budget.
The study concluded that the MCDA process helps to increase
communication across silos, to develop shared understanding of
the portfolio as a whole, and the transparency also makes it easy
to brief upwards, and provides an audit trail of the decision-
making process.
Local Commissioning—A Local Health Care Planner in the
English National Health Service
Isle of Wight Primary Care Trust used MCDA to support the
allocation of resources across 21 interventions in ﬁve priority
areas of respiratory, mental, and children’s health, cardiovascu-
lar disease, and cancer [27].
Key stakeholders engaged in the analysis were clinicians,
council representatives, voluntary sector representatives, nurses,
public and patients’ representatives, hospital managers, and the
ambulance service. An impartial facilitator worked iteratively
with key stakeholders to generate a formal, requisite model to
assess options on multiple criteria using MCDA and to generate a
summary beneﬁt score. Interventions were assessed on three
criteria: increased health (reduced mortality and increased qual-
ity of life), reduced health inequalities, and operational and
political feasibility.
The research team collected data on the performance of these
interventions on these criteria, and MCDA modeling was used to
estimate the total value of each intervention. The information on
value was combined with data on the cost to generate a priority
list in which interventions were ranked according to value for
money. Sensitivity analysis was used to explore the uncertainties
and disagreements among participants.
The proposed investment plan based on the ﬁnal priority list
was approved by the Isle of Wight Primary Care Trust Board. The
study concluded that MCDA has the potential to support local
health planners in their task of allocating ﬁxed budgets to a wide
range of types of health care.
Shared Decision Making—Evaluating Cancer Screening
Alternatives
Multiple screening options are available for people at average risk
for colorectal cancer, and the US colorectal cancer screening
guidelines recommend that screening decisions should reﬂect
individual patient preferences. AHP, an MCDA technique, was
used to elicit the decision priorities of people at average risk for
colorectal cancer attending four primary care practices (Roches-
ter, New York, Birmingham, and Indianapolis) in the United
States [35].
On the basis of American guideline statements, the research-
ers identiﬁed six criteria: ability to prevent cancer, avoidance of
side effects, minimizing false positives, and logistical complexity,
further divided into three subcriteria: frequency of testing,
preparation required, and method of testing procedure. Partic-
ipants were asked to indicate the relative importance of two
criteria on a scale of 1 to 9, where 1 indicates that the criteria are
equally important and 9 indicates that one criterion is extremely
important relative to the other. All comparisons were made on an
interactive computer program developed in Microsoft Excel,
which was then used to calculate the priorities assigned by the
participants to the decision criteria and subcriteria.
Patients were also asked several questions about the feasi-
bility of using AHP. A high proportion (92%–93% across the sites
in which the study was undertaken) of the 484 participants
indicated that it was not hard to understand the criteria; most
found it easy to follow the pairwise comparison process (91%)
and make the comparisons (85%). The majority (88%) stated that
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 1 – 1 3 7they would be willing to use a similar procedure to help make
important health care decisions. Thus, the study concluded that
patients are able and willing to perform such a complex AHP
analysis and that it was possible to use these techniques to foster
patient-centered decision making.
Prioritizing Patients’ Access to Elective Services
New Zealand’s Ministry of Health has worked with 1000Minds, an
MCDA tool, to create new points systems based on a consensus of
clinical judgments for prioritizing patients for access to elective
services in New Zealand [36].
These points systems were developed using MCDA processes,
supported by Internet‐based software, by a working group of
clinical leaders for the elective service concerned, in consultation
with patient groups and other clinicians.
The points systems consist of criteria for deciding patients’
relative priorities for treatment, in which each criterion is
demarcated into two or more categories. Each category is worth
a certain number of points intended to reﬂect both the relative
importance of the criterion and its degree of achievement. Each
patient is “scored” on the criteria and their corresponding point
values summed to get a “total score,” by which patients are
ranked (prioritized) relative to each other.
The process was initially applied to coronary artery bypass
graft surgery and then successively to other elective services. The
points systems for coronary artery bypass graft surgery, hip and
knee replacements, cataract surgery, plastic surgery, otorhinolar-
yngology, and many others have been endorsed by their profes-
sional organizations (e.g., New Zealand Orthopaedic Association)
and are in use throughout New Zealand.
Other Applications
Marsh et al. [8] and Adunlin et al. [40] recently published reviews
of MCDA in health care. Most (56%) of the MCDAs reviewed by
Marsh et al. were undertaken to support health care investment
decisions, such as HTA and national and local coverage decisions.
However, MCDAs were also identiﬁed supporting authorization
(12%) and prescription decisions (22%), and the allocation of
health research funding (2%). Adunlin et al. report that the most
frequent use of MCDA was in the area of diagnostics and treat-
ment (39%), but again a diversity of application areas was also
identiﬁed, including formulary management, geographic infor-
mation systems, HTA, medical automation, organ transplanta-
tion, pain management, performance measurement, priority
setting, professional practice, public health and policy, resource
planning, site selection, and supply chain.
A common ﬁnding between these articles is the diversity of
decisions for which MCDA techniques are applied and the wide
variety of MCDA methods used. The next section describes the
MCDA modeling approaches available.MCDA Modeling Approaches
MCDA approaches can be broadly classiﬁed into value measure-
ment models, outranking models, and reference-level models [41]: Value measurement models involve constructing and com-
paring numerical scores (overall value) to identify the degree
to which one decision alternative is preferred over another.
They most frequently involve additive models (sometimes
referred to as “weighted-sum” models, or “additive multi-
attribute value models”), which multiply a numerical score for
each alternative on a given criterion by the relative weight for
the criterion and then sum these weighted scores to get a
“total score” for each alternative. Outranking methods typically involve making pairwise com-
parison of alternatives on each criterion, which, in turn, are
then combined to obtain a measure of support for each
alternative being judged the top-ranked alternative overall.
Outranking algorithms include the ELimination and Choice
Expressing Reality (ELECTRE) family of methods [42–44], Pref-
erence Ranking Organization Method for Enrichment of Eval-
uations (PROMETHEE) [45], and geometrical analysis for
interactive aid (GAIA) [46]. Reference-level modeling involves searching for the alterna-
tive that is closest to attaining predeﬁned minimum levels of
performance on each criterion [47]. These are broadly based
on linear programming techniques and include goal, or
aspiration methods [11].
As described in the second section, other MCDA methods not
based on formal modeling also exist. At the most rudimentary
level, the alternatives’ performance on criteria can simply be
reported in a table, known as a “performance matrix” or “con-
sequences table” [20]. This matrix/table can be used, in effect, as
an aide-mémoire for decision makers’ deliberations focused on
reaching a consensus ranking or choice of the “best” alternative
(depending on the nature of the decision being made).
Value measurement approaches are by far the most widely
used in health care [8], with outranking and goal programming
approaches much less commonly used. However, which MCDA
model is most appropriate depends on the objective of the
analysis and the nature of decision makers’ preferences. There
is often no simple answer to which approach is best suited to
which decision problem. Those undertaking MCDA should
always provide a clear rationale for opting for one approach over
another, and ensure that it is compatible with the decision
problem being addressed (see second task force report published
in a later issue for further guidance). For example, value meas-
urement approaches should be selected when decision makers
consider criteria to be compensatory; that is, an improvement in
one criterion can compensate for a worsening in another. Out-
ranking methods may be useful if the goal is to identify a small
subset of alternatives that fulﬁll a minimum requirement from a
large set of alternatives (because developing a total value score
using weighted-sum models for each alternative is not efﬁcient).An Overview of Steps in Conducting an MCDA
The focus of the task force reports is on the value measurement
approaches because other techniques are rarely used in health
care [8]. Although there are many differences in the ways in
which these models are used and applied, there are several main
elements of the process that are common among these methods.
Broadly speaking, any value measurement modeling approach
entails deﬁning the decision problem being addressed, selecting
the criteria, measuring alternatives’ performance, scoring alter-
natives and weighting criteria, aggregation, uncertainty analysis,
and interpretation of results.
Several comprehensive descriptions of the steps involved in
conducting MCDA have been published [5,11], and there are many
MCDA software available for supporting these steps [48,49]. An
overview of the main steps involved in conducting an MCDA is
presented in Table 2. It is important to emphasize that the steps
can be performed in a different sequence and the process of
undertaking an MCDA is iterative, rather than comprising a
strictly sequential set of steps. Also, the performance matrix
produced after the ﬁrst three steps can be used to support
deliberative decision making (i.e., “partial” MCDA without explicit
weighting and scoring).
Table 2 – Steps in a value measurement MCDA
process.
Step Description
Deﬁning the decision
problem
Identify objectives, type of decision,
alternatives, stakeholders, and
output required
Selecting and
structuring criteria
Identify criteria relevant for evaluating
alternatives
Measuring
performance
Gather data about the alternatives’
performance on the criteria and
summarize this in a “performance
matrix”
Scoring alternatives Elicit stakeholders’ preferences for
changes within criteria
Weighting criteria Elicit stakeholders’ preferences
between criteria
Calculating aggregate
scores
Use the alternatives’ scores on the
criteria and the weights for the
criteria to get “total value” by which
the alternatives are ranked
Dealing with
uncertainty
Perform uncertainty analysis to
understand the level of robustness
of the MCDA results
Reporting and
examination of
ﬁndings
Interpret the MCDA outputs, including
uncertainty analysis, to support
decision making
MCDA, multiple criteria decision analysis.
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these eight steps and the methods alternatives available within each
step. The second task force report will provide further guidance on
selecting and implementing these methods. For illustrative purposes,
a simple worked example of scoring, weighting, and aggregation in
an additive model is provided in the Appendix.
Deﬁning the Decision Problem
The starting point for any MCDA involves understanding and
deﬁning the decision problem and the corresponding decision
goal. This also involves identifying the appropriate stakeholders,
the alternatives under consideration, and the output required. As
seen in Table 1, the stakeholders, depending on the application,
may include patients, clinicians, payers, regulators, and the
general population. In some applications, stakeholders might be
acting on behalf of others (e.g., an HTA committee making
decisions in the interests of the general population), whereas in
other applications, the stakeholders may be the decision makers
themselves (e.g., patients in shared decision making). The types
of decision problems can vary (e.g., understanding the value of
alternatives or to rank/categorize the alternatives, as seen in
Table 1), and can include one-off problems (e.g., patient choosing
between treatment alternatives) or repeated problems (e.g.,
reimbursement decisions at HTA agencies).
Selecting and Structuring Criteria
Once the decision problem has been identiﬁed, the next step is to
identify and agree on the criteria by which the alternatives will be
evaluated. For example, as observed in Table 1, authorization
decisions may be informed exclusively by clinical outcomes,
whereas prioritization decisions may incorporate a broader set
of criteria. Criteria can be identiﬁed in a number of ways, from
reviews of previous decisions to focus groups and facilitated
workshops. The criteria used in an additive model should meetcertain requirements such as completeness, nonredundancy,
nonoverlap, and preferential independence (see the second task
force report for further information on these requirements). Once
the criteria have been identiﬁed, they can be structured using
“value trees” [50], which decompose the overall value into criteria
and subcriteria in a visual manner.Measuring Performance
Once the criteria are agreed upon, the performance of the alter-
natives on each of the criteria is determined (e.g., gathering
evidence that drug A leads to a mean overall survival of x months
and the overall survival with drug B is y months). Data on the
alternatives’ performance on each of the criteria can be gathered
in various ways, ranging from standard evidence synthesis tech-
niques (e.g., systematic reviews and meta-analysis) to elicitation of
expert opinion in the absence of “harder” data. The alternatives’
performance on criteria can be reported in a table, known as a
“performance matrix” [20]. As described earlier, this “performance
matrix” can be used, in effect, as an aide-mémoire for decision
makers’ deliberations without explicit scoring and weighting.Scoring Alternatives
Following the analysis of the alternatives’ performance, stake-
holders’ priorities or preferences for changes within criteria
(scores) are captured. Scores are often derived by deﬁning rules
or functions for converting performance measurements into
scores. In this instance, the scores differ from performance
measures in two ways. First, scores are often used to translate
performance measures using different units for each criterion
onto a common scale, for instance, a 0 to 100 scale. Second,
scores incorporate priorities or preferences for changes in per-
formance within criterion, converting performance measures
into scores such that the same change along the scoring scale
(e.g., 10–20 or 60–70) is equally preferred.
Scoring elicitation methods can be broadly deﬁned as “com-
positional” and “decompositional”; compositional methods look
at each criterion separately and build up the overall value,
whereas decompositional methods look at the overall value of
alternatives as a whole, from which weights and scores for
criteria are derived.
Compositional methods generate separate estimates of scores
and weights, which are then combined in subsequent steps of the
MCDA (step 6). In the Keeney and Raiffa MCDA approach, the
scores are generated by tracing out the shape of the “value
function” that relates alternatives’ performance on the criterion
to their value to decision makers (e.g., using “bisection” and
“difference” methods [51,52]). A number of other compositional
methods have been applied to generate scores, including direct
rating (visual analogue scale, points allocation) [53], Simple Multi
Attribute Rating Technique [54]), and pairwise comparison (e.g.,
AHP [55] and Measuring Attractiveness by a Categorical Based
Evaluation Technique (MACBETH) [56]). See Appendix for a
simple example of the Keeney and Raiffa MCDA. For further
detail about these other methods, the readers are encouraged to
read the second task force report.
In contrast, decompositional methods—including DCEs or
conjoint analysis [57–59] and Potentially All Pairwise RanKings
of all possible Alternatives (PAPRIKA) [60]—involve participants
ranking two or more real or hypothetical alternatives deﬁned on
some or all of the criteria. For DCEs, weights and scores are
derived from these rankings simultaneously using regression-
based techniques, in the form of coefﬁcients estimating how the
preference for, or utility associated with, an alternative varied
with changes in performance against each criteria. PAPRIKA uses
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estimate weights and scores simultaneously.
Weighting Criteria
Weighting involves eliciting stakeholders’ preferences between
criteria. Weights represent “trade-offs” between criteria and are
used to combine the scores on individual criterion into a measure
of “total value.” Weighting can be thought of as analogous to
setting exchange rates—the scores on different criteria all repre-
sent value (e.g., as euros, US dollars, and UK pounds do)—but
they are not commensurate and have to be made commensurate
by applying weights (i.e., exchange rates).
In the Keeney and Raiffa MCDA approach, the weights are
elicited using “swing weighting” by taking into account the ranges
of performance relevant to a set of alternatives (i.e., the “swing” in
performance). A number of other compositional methods have
also been applied to generate weights, including direct rating
(visual analogue scale, direct rating, and points allocation) [53]
and Simple Multi Attribute Rating Technique [54]) and pairwise
comparison (e.g., AHP [55] and MACBETH [56]). Weights can also
be estimated using decompositional methods such as DCEs,
conjoint analysis [57–59], and PAPRIKA [60].
Scoring and weighting is usually done by the stakeholders,
who at times can also be decision makers. For example, a patient
using an MCDA approach as a decision aid in choosing between
treatment alternatives is the sole stakeholder/decision maker. In
other applications, it is less clear-cut whose scores/weights
should be used. For example, in HTA, criteria weights could come
from committee members, from patients, or from the general
public. The choice about whose preferences are relevant to a
given decision problem is a normative one, and the outcome
from the decision-making process may be sensitive to which and
whose scores/weights are used.
Calculating Aggregate Scores
Value measurement models often use the additive model for
computing aggregate results. For the compositional methods and
the PAPRIKA (decompositional) method [60], each alternative’s
scores on the criteria are multiplied by the weights and these
weighted scores are then summed across the criteria to get a
“total value” for each alternative. With conjoint analysis or a DCE
method, the data on performance of the alternatives are input
into the valuation function derived from regression analysis to
estimate each alternative’s value (or “utility”) or its probability of
being the preferred alternative. Other types of aggregative meth-
ods such as multiplicative models [51,61] can also be used with
value measurement models but are relatively rare [8].
Dealing with Uncertainty
Uncertainty may affect both the design and evidence feeding into
the assessment. All aspects of MCDA such as what criteria are
selected, performance against those criteria, and whose views
should inform the weighting/scoring of criteria are subject to
uncertainty [62]. It is important to understand the impact that
this uncertainty has on MCDA results, to evaluate the robustness
of the decision outcomes. Parameter uncertainty (e.g., uncer-
tainty in the performance of alternatives) can be addressed using
techniques such as probabilistic sensitivity analysis techniques.
Structural uncertainty (e.g., choice of criteria) can be addressed
using scenario analyses; for example, different sets of criteria can
be used to understand whether the results from the MCDA
exercises differ. Heterogeneity in preferences among subgroups
can be studied by using weights and scores obtained from
different stakeholder groups in the MCDA model.Interpretation and Reporting the Results
MCDA results can be presented in tabular or graphical form for
decision makers. Aggregate value scores can be interpreted and
used in different ways, that is, to rank the alternatives in order of
importance or providing a measure of value for each of the
alternatives. Alternatives’ total scores can also be combined with
cost data to identify “value for money” of each alternative to
allow portfolio or resource allocation decisions. Also, it is worth-
while emphasizing that MCDA is intended to serve as a tool to
help decision makers reach a decision—their decision, not the
tool’s decision. The decision makers/stakeholders can be pre-
sented with the MCDA model to allow them to explore the results
for different scenarios. The exceptions are “algorithmic” MCDA
frameworks such as points systems for prioritizing elective
services [36] and multicriteria organ allocation algorithms [37].
These “algorithmic” frameworks are relatively rare in health care,
and are used where the aim of the tools is to minimize the
human factor, for either potential positive or negative discrim-
ination, in making decisions.Conclusions
MCDA can support decision making in health care. It improves
transparency and consistency in decisions—and potentially, the
accountability of public sector decision makers. It does not
replace judgment, but rather identiﬁes, collects and structures
the information required by those making judgements to support
the deliberative process. This report deﬁnes MCDA, provides an
overview of the wide range of applications and describes the key
steps involved. It will be helpful for those with little knowledge of
MCDA. The second MCDA task force report goes into more depth
providing guidance on how to choose the MCDA method as well
as a good practice guidelines checklist and recommendations. It
will be particularly useful for those designing and reviewing
MCDA applications in health care.Acknowledgments
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Fig. A2 – Linear partial value function for criterion B.
Fig. A3 – Nonlinear partial value function for criterion C.
Fig. A1 – Linear partial value function for criterion A.
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We present here a stylized hypothetical example to demonstrate
the Keeney and Raiffa MCDA approach, which involves scoring
using “partial value functions” and “swing” weighting. For illus-
trative purposes, the decision problem is kept quite simple (with
three criteria and two alternatives) and described in abstract
terms (e.g., “alternative 1”). However, the same principles can be
extended to any MCDA problem.
Let us assume that after completing the ﬁrst three steps of
MCDA, the performance matrix generated is as presented in Table
A1. Note that aa, bb, and cc are the units used to measure criteria A,
B, and C, respectively. Criteria A and C are measured in units where
higher performance is better, whereas criterion B is measured in
units where lower performance is better (e.g., frequency of adverse
events). Organizing the evidence in this kind of performance
matrix might in itself help decision makers weigh up multiple
criteria, by highlighting the trade-offs that need to be made. For
example, alternative 1 outperforms alternative 2 on criteria A and
C, but alternative 2 outperforms alternative 1 on criterion B
(because lower performance in criterion B is better). MCDA canhelp aggregate the performance in these criteria, measured in
different units, into a single overall value for each alternative. To
do so requires us to establish the preferences of decision makers
within and between criteria, via scoring and weighting.
Scoring
Scores on a criterion differ from performance measures on a
criterion in two important ways. First, scores are often used to
translate performance measures using different units for each
criterion onto a common scale. Second, scores incorporate prefer-
ences for changes in performance, such that the same change
along the scoring scale (e.g., 10–20 or 60–70) is equally preferred.
Scoring in this example is performed on the measurement
scale for each criterion: 65–90 aa for criterion A, 5–10 bb for
criterion B, and 0–1 cc for criterion C. It is assumed that these
scales represent the feasible ranges for each criterion.
When the ranges of each criterion have been identiﬁed, partial
value functions are developed to specify the relationship between
changes along these ranges of performance and their value (i.e.,
the score that will be input into the MCDA, often deﬁned on a scale
of 0–100 points). There are two factors to consider when establish-
ing the partial value functions: 1) whether the relationship
between changes along these ranges of performance and the score
is linear and 2) whether high performance is better (e.g., treatment
effectiveness) or low performance is better (e.g., adverse events). If
a linear function deﬁnes this relationship, the speciﬁcation of the
partial value function is straightforward, as shown in Figures A1
and A2. It is assumed that both criteria A and B have a linear
partial value function, but higher performance in criterion A is
better whereas lower performance in criterion B is better.
If this function is nonlinear, there are a number of methods that
can support the elicitation of these functions from stakeholders
[51,52]. For example, a partial value function for the 0–1 cc range of
criterion C could be developed by answering the following question:
“What level is x so positioned that a change from 0 cc (i.e., worst
value with a score of 0 points) to x cc gives you as much value as a
change from x cc to 1 cc (i.e., the most desirable value with a score of
100 points)?” This process can be iterated for several points in the
scale to understand the shape of the value function. This method to
derive partial value functions is known as the “bisection method.”
Figure A3 shows the nonlinear function describing the rela-
tionship between partial values scores and the performance on
criterion C. It can be observed that there is steep increase in
scores until up to performances of 0.3 cc after which the relation-
ship slows down slightly. For example, the increase in the scores
as a result of going from 0.55 cc to 0.63 cc is only 5 points, whereas
the same increase in the performance earlier (from 0.15 cc to 0.23
Fig. A4 – Illustration of swing weighting. (Color version of ﬁgure available online.)
Table A1 – Performance matrix.
Criteria Alternative 1 Alternative 2
A 85 aa 73 aa
B 8 bb 6.5 bb
C 0.23 cc 0.15 cc
Table A2 – Aggregation to estimate the overall value of the alternatives.
Criteria Scores for alternative 1 Scores for alternative 2 Weights Alternative 1 Alternative 2
Criterion A 80 32 0.25 80  0.25 ¼ 20 32  0.25 ¼ 8
Criterion B 40 70 0.42 40  0.42 ¼ 16.8 70  0.42 ¼ 29.4
Criterion C 65 55 0.33 65  0.33 ¼ 21.45 55  0.33 ¼ 18.15
Overall value of
the alternatives
58.25 55.55
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preference for increases in performance in criterion C depends on
the baseline measure of the performance, with a similar increase
in performance valued more highly when the baseline perform-
ance is low rather than when the baseline performance is high.
Weighting
The partial value scores on different criteria all represent value,
but they have to be made commensurate into a measure of “total
value,” which is performed by applying weights. Weighting
involves eliciting stakeholders’ preferences between criteria as
“trade-offs” and can be thought of as setting exchange rates (e.g.,
to combine €, $, and £ into a single overall value).
The ﬁrst step in the swing weighting exercise is to identify and
assign 100 points to the criterion with the swing (range of perform-
ance) that matters most. This is followed by a pairwise comparison
between this criterion and each of the others to determine the
relative importance of swings in criteria, and correspondingly
allocate the points between 0 and 100. For example, if criterion B
was assigned 100 points, we might ask stakeholders: “If a decreaseof 10 bb to 5 bb in criterion B is given 100 points, on a scale of 0 to
100 how important is an improvement in the criterion A from 65 aa
to 90 aa?” This process is then repeated for all remaining criteria to
obtain an estimate of the relative value of the swing on each
criterion, as shown in Figure A4.
Let us assume that after completing the weighting exercise,
the points allocated for criteria A, B, and C are 60, 100, and 80.
These are then normalized (i.e., dividing each criterion’s points
by the sum of points) so that the weights add up to 1, resulting in
weights of 0.25, 0.42, and 0.33, respectively.Aggregation
After eliciting the scores and the weights, the aggregation is
frequently performed using an additive model. For each alter-
native, this involves multiplying the scores of the alternative on
the criterion with the weight of that criterion and summing
across criteria. The scores, weights, and the total “value” of the
two alternatives are presented in Table A2.
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alternative 2 is 55.55, which suggests that alternative 1 is
preferable.Uncertainty Analysis
The results from MCDA should not be taken as the “ﬁnal
decision” but rather the MCDA model should be used to
explore the uncertainty in the decision problem. The decision
makers can be presented with results from analyses exploring
different types of uncertainty (e.g., parameter uncertainty,
structural uncertainty, and heterogeneity) to support decision
making. A simple example of scenario analysis is presented
here.
Let us assume that there is uncertainty about the performance
of alternative 2 on criterion B and that another source suggests
that this performance is 6 bb (instead of 6.5 bb). Using the partial
value function for criterion B in Figure A2, it can be estimated that
the score of alternative 2 on criterion B is now 80 (instead of 70).
Using this score in Table A2 results in an overall value of 59.75,
which suggests that alternative 2 is preferable. Threshold analysis
can also be performed to determine at which point of performance
alternative 2 becomes the preferred alternative.
MCDA is intended to serve as a tool to help decision
makers reach a decision—their decision, not the tool’s decision.
The decision makers can deliberate on which is the most
appropriate evidence (and thus, the most appropriate score and
the most appropriate “total value”) before making their ﬁnal
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